Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

Shares of Merck & Co. Inc. MRK inched 0.08% higher to $99.45 Tuesday, on what proved to be an all-around favorable trading ...

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...